KalVista Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: KALV · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $520,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, filing
Related Tickers: KALV
TL;DR
KalVista Pharma filed an 8-K on Oct 6, 2025, detailing leadership changes and financial exhibits.
AI Summary
KalVista Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
Why It Matters
This 8-K filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine corporate events and disclosures, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36830 (commission_file_number) — SEC File Number
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided excerpt.
Are there any new compensatory arrangements for officers detailed in this filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specifics of these arrangements are not provided in the excerpt.
What is the significance of the 'Regulation FD Disclosure' item in this report?
Regulation FD Disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure to certain investors.
What types of financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these statements and exhibits is not detailed in the provided text.
What was KalVista Pharmaceuticals' former company name, and when did the name change occur?
KalVista Pharmaceuticals, Inc. was formerly known as Carbylan Therapeutics, Inc. after a name change on September 16, 2014. Prior to that, it was Carbylan Biosurgery, Inc. after a name change on January 2, 2013, and originally Carbylan Biosurgery Inc. after a name change on January 5, 2006.
Filing Stats: 1,123 words · 4 min read · ~4 pages · Grade level 11.3 · Accepted 2025-10-06 07:15:18
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value Per Share KALV The Nasdaq
- $520,000 — that provides for (i) a base salary of $520,000 per year, (ii) an annual bonus target e
Filing Documents
- d42627d8k.htm (8-K) — 31KB
- d42627dex101.htm (EX-10.1) — 54KB
- d42627dex991.htm (EX-99.1) — 11KB
- 0001193125-25-230906.txt ( ) — 227KB
- kalv-20251006.xsd (EX-101.SCH) — 3KB
- kalv-20251006_lab.xml (EX-101.LAB) — 17KB
- kalv-20251006_pre.xml (EX-101.PRE) — 11KB
- d42627d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit Number Description of Exhibit 10.1 Form of Indemnification Agreement. 99.1 Press Release issued October 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: October 6, 2025 By: /s/ Brian Piekos Brian Piekos Chief Financial Officer